

Illumina to buy PacBio for \$1.2 billion

January 2019—Illumina announced it will acquire Pacific Biosciences for approximately \$1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina's short-read sequencing platforms and PacBio's long-read sequencing capabilities to help researchers advance their discoveries faster and to help clinicians offer new tests economically. Illumina expects to close the transaction in mid-2019.

[Illumina](#), 858-202-4500